Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BOLT
stocks logo

BOLT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
820.80K
-28.06%
-5.518
-34.32%
633.33K
-48.17%
-3.600
-37.93%
--
--
-3.520
-21.08%
Estimates Revision
The market is revising Upward the revenue expectations for Bolt Biotherapeutics, Inc. (BOLT) for FY2025, with the revenue forecasts being adjusted by 6.58% over the past three months. During the same period, the stock price has changed by 2.31%.
Revenue Estimates for FY2025
Revise Upward
up Image
+6.58%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+46.35%
In Past 3 Month
Stock Price
Go Up
up Image
+2.31%
In Past 3 Month
Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 29.33 USD with a low forecast of 6.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 29.33 USD with a low forecast of 6.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.310
sliders
Low
6.00
Averages
29.33
High
75.00
Current: 5.310
sliders
Low
6.00
Averages
29.33
High
75.00
H.C. Wainwright
NULL -> Buy
initiated
$7
2025-10-20
Reason
H.C. Wainwright
Price Target
$7
2025-10-20
initiated
NULL -> Buy
Reason
H.C. Wainwright assumed coverage of Bolt Biotherapeutics with a Buy rating and $7 price target. The company's lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead, the analyst tells investors in a research note. The firm says initial clinical results for BDC-4182 are expected in Q3 of 2026.
Lake Street
Chad Messer
Buy
maintain
$4 -> $75
2025-08-15
Reason
Lake Street
Chad Messer
Price Target
$4 -> $75
2025-08-15
maintain
Buy
Reason
Lake Street analyst Chad Messer raised the firm's price target on Bolt Biotherapeutics to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2 with $48.5M in cash and reiterated its cash runway through mid-2026. The company completed a 20:1 reverse stock split to regain compliance with Nasdaq listing requirements in June, notes the analyst, who adjusted the firm's target to account for the reverse split.
Stifel
Stephen Willey
Hold
downgrade
$1
2025-05-13
Reason
Stifel
Stephen Willey
Price Target
$1
2025-05-13
downgrade
Hold
Reason
Stifel
Stephen Willey
Hold
Maintains
$1.5 → $1.25
2025-03-25
Reason
Stifel
Stephen Willey
Price Target
$1.5 → $1.25
2025-03-25
Maintains
Hold
Reason
Stifel lowered the firm's price target on Bolt Biotherapeutics to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of patient enrollment into the Phase 1 single-agent BDC-3042 dose-escalation trial sets the stage for a medical conference presentation in Q2, but the firm continues to believe the competitive intensity of the CLDN18.2 drug development landscape establishes a high safety/efficacy hurdle, the analyst tells investors.
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-25
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-25
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bolt Biotherapeutics Inc (BOLT.O) is -0.34, compared to its 5-year average forward P/E of -1.59. For a more detailed relative valuation and DCF analysis to assess Bolt Biotherapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.59
Current PE
-0.34
Overvalued PE
0.66
Undervalued PE
-3.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.62
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.69
Undervalued EV/EBITDA
-3.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
56.52
Current PS
0.00
Overvalued PS
166.26
Undervalued PS
-53.22
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BOLT News & Events

Events Timeline

(ET)
2025-11-12
16:49:42
Bolt Biotherapeutics announces Q3 EPS of $3.72, below consensus estimate of $5.39
select
2025-10-01 (ET)
2025-10-01
16:07:29
Bolt Biotherapeutics to Cut Workforce by Half and Provide Update on BDC-4182 Study
select
2025-08-14 (ET)
2025-08-14
16:14:03
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-13NASDAQ.COM
Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements

  • Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.

  • Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.

  • Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.

  • Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.

[object Object]
Preview
4.0
10-20Benzinga
HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
9.0
04-26Newsfilter
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

  • Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.

  • Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bolt Biotherapeutics Inc (BOLT) stock price today?

The current price of BOLT is 5.31 USD — it has increased 0.76 % in the last trading day.

arrow icon

What is Bolt Biotherapeutics Inc (BOLT)'s business?

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

arrow icon

What is the price predicton of BOLT Stock?

Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 29.33 USD with a low forecast of 6.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bolt Biotherapeutics Inc (BOLT)'s revenue for the last quarter?

Bolt Biotherapeutics Inc revenue for the last quarter amounts to 2.17M USD, increased 90.10 % YoY.

arrow icon

What is Bolt Biotherapeutics Inc (BOLT)'s earnings per share (EPS) for the last quarter?

Bolt Biotherapeutics Inc. EPS for the last quarter amounts to -3.72 USD, decreased -53.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bolt Biotherapeutics Inc (BOLT)'s fundamentals?

The market is revising Upward the revenue expectations for Bolt Biotherapeutics, Inc. (BOLT) for FY2025, with the revenue forecasts being adjusted by 6.58% over the past three months. During the same period, the stock price has changed by 2.31%.
arrow icon

How many employees does Bolt Biotherapeutics Inc (BOLT). have?

Bolt Biotherapeutics Inc (BOLT) has 52 emplpoyees as of December 05 2025.

arrow icon

What is Bolt Biotherapeutics Inc (BOLT) market cap?

Today BOLT has the market capitalization of 10.19M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free